WO2008110070A1 - Comprimé double comprenant un médicament labile sous l'action d'un acide - Google Patents

Comprimé double comprenant un médicament labile sous l'action d'un acide Download PDF

Info

Publication number
WO2008110070A1
WO2008110070A1 PCT/CN2008/000475 CN2008000475W WO2008110070A1 WO 2008110070 A1 WO2008110070 A1 WO 2008110070A1 CN 2008000475 W CN2008000475 W CN 2008000475W WO 2008110070 A1 WO2008110070 A1 WO 2008110070A1
Authority
WO
WIPO (PCT)
Prior art keywords
sheet
layer
unit tablet
sodium
amount
Prior art date
Application number
PCT/CN2008/000475
Other languages
English (en)
Chinese (zh)
Inventor
Jianhui Guo
Yaoru Lu
Haiying He
Original Assignee
Shanghai Allist Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Allist Pharmaceuticals, Inc. filed Critical Shanghai Allist Pharmaceuticals, Inc.
Priority to CN2008800032753A priority Critical patent/CN101626755B/zh
Publication of WO2008110070A1 publication Critical patent/WO2008110070A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Definitions

  • the present invention relates to the field of pharmaceutical preparations, and more particularly to a solid pharmaceutical preparation comprising an acid labile drug, particularly a proton pump inhibitor, and a preparation method and use thereof.
  • H+ / K+ - triuretic adenosinease ( ⁇ " ⁇ + ⁇ - chymase) inhibitors also known as proton pump inhibitors (PPIs)
  • PPIs proton pump inhibitors
  • omeprazole lansoprazole ( Lansoprazole ), pantoprazole, rabeprazole, tenatoprazole: pariprazole, leminoprazole and others.
  • the compound may be used in a neutral form or in the form of an alkali salt, for example, in the form of a magnesium salt, a calcium salt, a sodium salt or a potassium salt, a single enantiomer of the compound or an alkali salt thereof, or a solvent may also be used.
  • the form of the compound is used.
  • These drugs inhibit gastric acid secretion by irreversibly and specifically inhibiting the K+-ATPase enzyme system located on the secretory surface of the gastric parietal cells.
  • These active substances are useful for inhibiting gastric acid secretion in mammals, especially humans. Therefore, it can be used to treat diseases associated with excessive gastric acid secretion, such as gastrinoma, gastric ulcer, duodenal ulcer, severe erosive esophagitis, and pathological gastric acid secretion.
  • Other symptoms can also be used to relieve symptoms associated with other causes such as taking NSAIDs cause gastric mucosal damage.
  • enteric coating i.e., coating with an enteric material.
  • enteric coating formulations are described in Chinese Patent No. ZL96193594.4, ZL96190090.3, U.S. Patent No. 4,786,505, and European Patent No. EP0519365.
  • the formulation comprises a core of pellet or core, a buffer coating, and an enteric coating of the outer layer.
  • a buffer coat layer having a certain thickness is required in the enteric coating layer. This means that in order to protect the stability of PPIs, multiple coatings are required. These all increase the formulation process and also increase the weight of the formulation, which is not beneficial for the patient. Some operations in the preparation process, such as high temperature operation during coating and collision of particles, deformation of the coated enteric coated particles during tableting, or uneven coating thickness, may also lead to drug expectations. Unstable.
  • a formulation that avoids the tablet compression process such as a suspension, as specifically A US-listed omeprazole dry suspension consisting of omeprazole, sodium bicarbonate and magnesium hydroxide, and excipients.
  • This preparation still needs to be enteric coated; and therefore it is bulky and needs to be dispersed before taking it, so it is inconvenient to take it; in addition, as a dry powder preparation, its packaging requirements are relatively high.
  • a similar prior art is also a two-layer chewable tablet as described in WO2004066924, the oral rapid disintegration preparation described in CN01820259.4.
  • a two-part tablet as described in the prior art such as CN02817249.3, which comprises an enteric-free inner core comprising (a) a proton pump inhibitor and an optional primary essential buffer, and b) coating the outer layer of the inner core comprising a primary essential buffer and an optional secondary essential buffer.
  • the main essential buffers independently include: sodium hydrogencarbonate, sodium sesquicarbonate, etc., and preferably sodium hydrogencarbonate.
  • the nucleus was uniformly coated with 975 mg of sodium hydrogencarbonate to form a layer of an external protective coating of sodium hydrogencarbonate.
  • Both the core and the outer cover are prepared using standard adhesives and other excipients to form a pharmaceutically acceptable finished tablet.
  • 750 mg of sodium bicarbonate and 10 mg of omeprazole powder form an inner core
  • 10 mg of omeprazole casing particles mixed with known binders and excipients form an outer core. After the entire tablet was taken, the tablet dissolved. The inner core is dispersed in the stomach and absorbed to achieve an immediate therapeutic effect.
  • the program still contains a casing section.
  • the buffer disintegrates and reaches the solution at a rate exceeding the PPIs, thereby providing the necessary p H to protect the PPIs before they dissolve and react with the acid in the environment.
  • the tablets or capsules can be made into an interior having a buffer-containing exterior and a mixture comprising PPIs or PPIs and a buffer. These production methods are designed to create a stable environment for PPIs during their residence time.
  • the technical solution provides for the prevention of degradation of PPIs by using a fast reacting buffer such as sodium bicarbonate and a slow reacting buffer such as magnesium oxide or magnesium hydroxide.
  • a fast reacting buffer such as sodium bicarbonate
  • a slow reacting buffer such as magnesium oxide or magnesium hydroxide.
  • One solution is: the inner layer of PPIs and sodium bicarbonate, and the outer layer of magnesium hydroxide xerogel or magnesia with a suitable disintegrant so that the magnesium oxide will rapidly disintegrate in the stomach.
  • the inner layer may comprise the magnesium buffer and the outer layer contains PPIs and sodium bicarbonate.
  • the solution is limited to preventing the degradation of PPIs by selecting the kind of buffer, such as the buffer neutralization speed and the amount of the buffer, that is, basically relying on the buffer and the gastric juice. Neutralization speed.
  • the protective effect of this method is often unreliable, such as tablets containing a variety of excipients, The granules are exposed from the excipients and the PPIs may be exposed to gastric juice and degraded prior to neutralization with gastric juice.
  • Another solution proposed in the patent application is to prepare a complex tablet having an inner layer and an outer layer.
  • the technical solution is also unreliable for the protection of PPIs.
  • PPIs may not raise the pH of the gastric juice after the outer layer disintegrates. When it is released, it may be exposed to gastric juice and degraded.
  • complex internal and external two-part tablets have certain difficulties in industrial production.
  • the two-unit tablet of the present invention overcomes the unreliability of the protection of PPIs, and starts from the excipients, and strictly and precisely controls the release time of the buffer (i.e., the alkalizing agent in the present invention) and PPIs, thereby ensuring The PPIs are released after the pH is raised to provide a safe protection; on the other hand, the two-unit tablet of the present invention is very suitable for industrial production, and now has similar forms of product production and sales; meanwhile, the present invention also It overcomes the shortcomings of the so-called internal and external double-layered complex tablets that are difficult to industrialize. Summary of the invention
  • the present invention provides an oral tablet containing an acid labile active ingredient, which avoids the complicated process of using an enteric material and the multiple coatings necessary thereby, by controlling the release sequence of the alkalizing agent and the active ingredient, thereby It ensures the stability of the acid labile active ingredient.
  • the present invention provides an oral tablet which is particularly suitable for PPIs, which can rapidly neutralize gastric acid after oral administration, release active ingredients, and provide sustained acid suppression.
  • the present invention achieves the above object by providing a two-unit tablet composed of two sheets of A and B.
  • the sheet A as an immediate release portion contains a sufficient amount of alkalizing agent and a high-performance disintegrating agent to allow it to rapidly disintegrate and release the alkalizing agent after entering the stomach;
  • the sheet B specifically contains a hindrance
  • the cleavage excipient also referred to as "blocking carrier” in the present invention
  • the high performance disintegrant, the acid labile active ingredient is dispersed in the retardation carrier.
  • the combination of the retardation carrier and the disintegrant allows the acid-labile active ingredient to be released in the alkalizing agent in the layer A and neutralized by the gastric acid, thereby preventing the stability of the acid-labile active ingredient while not being Will cause absorption delay.
  • the inventors have conducted intensive studies and found that by selecting an appropriate excipient, the two components can be strictly and sequentially released in a short period of time.
  • the acid labile active ingredient in the bi unit tablet of the present invention may be selected from the above-mentioned PPIs, specifically including omeprazole, pantoprazole, lansoprazole, rabeprazole, tetoprazole, pa Liraazole, lanololazole and its pharmacologically suitable racemates, basic salt forms, or one of their individual enantiomers or its basic salt form, or in the form of a solvate
  • Particularly preferred are pantoprazole sodium sesquihydrate, pantoprazole magnesium dihydrate, olaprazole magnesium, omeprazole and esomemagazole.
  • the amount of the active ingredient contained in the unit preparation of the two-unit tablet of the present invention is now The dosage of the clinically used preparation is consistent, such as omeprazole dose of 10mg, 20mg, 40mg, pantoprazole dose of 20mg, 40mg, lansoprazole dose of 15mg, 30mg, rabeprazole dose of 20mg, or Other effective doses clinically proven.
  • the alkalizing agent contained in the bi unit tablet of the present invention may be selected from, but not limited to, an electrolyte containing cationic sodium, potassium, calcium, magnesium, aluminum or cesium, such as sodium hydrogencarbonate, potassium hydrogencarbonate, magnesium lactate, magnesium carbonate.
  • These alkali compounds may be suitably used in the present invention either singly or in combination. It should be noted, however, that basophils which cause gastrointestinal mucosal irritation to produce too high a pH value are not suitable for use alone.
  • the retardation carrier contained in the sheet B in the bi unit tablet of the present invention is selected from the group consisting of pH-sensitive polymers and carrier materials having water swelling properties.
  • Sheet A contains an alkalizing agent and a disintegrant, and the necessary excipients. After a plurality of screening combinations, the inventors obtained an ideal combination of an alkalizing agent, a disintegrating agent and other excipients in the sheet A to disintegrate in an artificial gastric juice within 3 minutes to release an alkalizing agent.
  • the amount of the alkalizing agent in the sheet A is such as to neutralize the already existing gastric acid, and at the same time, it is desirable to have a faster neutralization speed.
  • the alkalizing agent in the sheet A is selected from the group consisting of sodium hydrogencarbonate, magnesium hydroxide and magnesium oxide. After neutralization of sodium bicarbonate with an equivalent amount of gastric acid (hydrochloric acid), the resulting pH is the pKa of its conjugate acid (carbonic acid), about 6.14 or greater, and magnesium hydroxide or magnesium oxide provides a sustained neutralization effect. , thus providing a safe pH environment for PPIs.
  • These alkalizing agents are used in an amount to neutralize about 4 to 10 moles of hydrochloric acid. In the unit preparation, the amount of sodium bicarbonate is 350 ⁇ 800 mgo
  • Sheet A also requires rapid disintegration after entering the body, so the use of excellent disintegrants, such as croscarmellose sodium, cross-linked polyvinylpyrrolidone, sodium carboxymethyl starch,
  • excellent disintegrants such as croscarmellose sodium, cross-linked polyvinylpyrrolidone, sodium carboxymethyl starch
  • the low-substituted hydroxypropylcellulose is used in an amount of 4% to 10% by weight based on the total weight of the layer A, and its effect is to prevent the disintegration time of the layer A in 150 ml of artificial gastric juice for not more than 3 minutes.
  • composition of the sheet layer A of the present invention is: using a combination of sodium hydrogencarbonate, magnesium hydroxide and magnesium oxide as an alkalizing agent, using crosslinked polyvinylpyrrolidone as a disintegrating agent, and adding a necessary filler, Excipients such as adhesives and lubricants.
  • the total amount of the alkalizing agent is required to neutralize about 4 to 10 mmol of hydrochloric acid.
  • the cross-linked polyvinylpyrrolidone is present in an amount of from 4% to 8% by weight based on the weight of the sheet A.
  • the filler may be selected from one or more of microcrystalline cellulose, mannitol, starch, pregelatinized starch, dextrin, sucrose, lactose, calcium sulfate, calcium phosphate
  • the binder may be selected from the group consisting of microcrystalline cellulose, mannitol, starch, pregelatinized starch, sucrose, lactose, calcium sulfate, calcium phosphate, and the like.
  • the lubricant may be selected from the group consisting of stearic acid, calcium stearate, One or more of magnesium stearate, talc, magnesium decyl sulfonate, polyethylene glycol, the surfactant may be selected from the group consisting of a Tween surfactant and sodium dodecyl sulfonate Wait.
  • Sodium bicarbonate can also be used alone in sheet A in an amount to neutralize about 4 to 10 moles of hydrochloric acid.
  • Sheet B is a drug-containing layer comprising an acid labile active ingredient, an alkalizing agent, a disintegrant, and an excipient having a retarding action, and other excipients necessary; wherein, acid labile activity
  • the ingredients are dispersed in a carrier having a retarding effect for the purpose of appropriately delaying the release. However, it should be clear that this temporary delay is within 10 minutes and does not cause delays in the release and absorption of active ingredients.
  • the active ingredient in sheet B is co-present with the basifying agent, and an alternative basifying agent such as the type of basifying agent mentioned in sheet A is used.
  • an alternative basifying agent such as the type of basifying agent mentioned in sheet A
  • the sum of the amount of the alkalizing agent in the sheet B and the amount of the alkalizing agent in the sheet A should be able to neutralize hydrochloric acid of 4 to 45 mEq.
  • the type/combination of the alkalizing agent and its amount are adjusted according to the stability of the active ingredient to pH. The purpose is to maintain the pH of the gastric juice at least +1 of the active ingredient during the stay of the drug in the stomach to prevent degradation. .
  • the retardation carrier is selected from the group consisting of pH-sensitive polymers and carrier materials having water swelling properties.
  • other materials having a retarding effect are also applicable to the object of the present invention, and are also included in the technical solution of the present invention.
  • the water-swellable carrier material is, for example, a highly swellable polymer when contacted with water or an aqueous medium, a polymer that forms a gel in contact with water or an aqueous medium, a polymer that contacts water or an aqueous medium having swelling and gelling properties.
  • a highly swellable polymer in contact with water or an aqueous medium such as gastric contents selected from the group consisting of sodium carboxymethylcellulose, crosslinked hydroxypropylcellulose, high molecular weight hypromellose, carboxymethylamide, potassium methacrylate Divinylbenzene copolymer, polymethyl methacrylate, crosslinked PVP, high molecular weight polyvinyl alcohol, and the like.
  • a polymer that forms a gel when exposed to water or an aqueous medium such as stomach contents selected from methyl cellulose, carboxymethyl fibers , low molecular weight hypromellose, low molecular weight polyvinyl alcohol, polyoxyethylene alcohol, non-crosslinked polyvinylpyrrolidone, xanthan gum, and the like.
  • a polymer capable of simultaneously expanding and forming a gel upon contact with water or an aqueous medium such as a stomach contents selected from the group consisting of medium and low viscosity hypromellose and medium and low viscosity polyvinyl alcohol.
  • hydrocolloids such as natural or synthetic gums, cellulose derivatives other than those listed above, sugar-based materials such as tragacanth, guar gum, agar, pectin. , carrageenan, soluble and insoluble alginate, carboxypolyethylene, casein, zein, etc., as well as proteinaceous materials such as gelatin.
  • medium to low viscosity hypromellose methyl cellulose, carboxymethyl cellulose, medium and low viscosity polyvinyl alcohol, non-crosslinked polyvinylpyrrolidone, xanthan gum and the like.
  • the above-mentioned carrier material and/or disintegrant having a retarding effect is selected to achieve precise control of the release time and speed of the active ingredient, which is neither instantaneous and rapid release, nor does it cause undesired delay or slowness. release.
  • a carrier material having water swelling properties is preferred.
  • Hydroxypropyl methylcellulose with a viscosity of 3 to 50 cP such as commercially available METHOCEL.E3 PREMIUM, METHOCEL E5 PREMIUM, METHOCEL E6 PREMIUM, PHARMACOAT 603, PHARMACOAT 606, PHARMACOAT 615, etc. 8% to 30% by weight; and crosslinked polyvinylpyrrolidone (PVPP XL) as a disintegrant in an amount of 6% to 8% based on the total weight of the sheet B.
  • METHOCEL.E3 PREMIUM, METHOCEL E5 PREMIUM, METHOCEL E6 PREMIUM, PHARMACOAT 603, PHARMACOAT 606, PHARMACOAT 615, etc. 8% to 30% by weight and crosslinked polyvinylpyrrolidone (PVPP XL) as a disintegrant in an amount of 6% to 8% based on the total weight of the sheet B.
  • the viscosity is 5 to 130 cP sodium carboxymethylcellulose, and the amount is 8% to 30% by weight of the layer B.
  • Low-substituted hypromellose is selected as the disintegrant in an amount of from 8% to 10% by weight of the sheet B.
  • Methylcellulose with a viscosity of 5 to 15 cP in an amount of 8% to 30% by weight of the layer B.
  • the croscarmellose sodium is used as a disintegrant in an amount of from 5 % to 10% by weight based on the weight of the sheet B.
  • Xanthan gum with a particle size of 200 mesh or more, in an amount of 5% to 20% by weight of the layer B.
  • the croscarmellose sodium is used as a disintegrant in an amount of 6% to 10% by weight of the sheet B.
  • the combination of the above-mentioned retardation carrier and disintegration is a main component of the sheet B of the present invention, and when it is compressed into a tablet, it is necessary to add other excipients such as a filler binder, a lubricant, and the like.
  • a filler binder such as a lubricant, and the like.
  • Surfactants, etc. The filler may be selected from one or more of microcrystalline cellulose, mannitol, starch, pregelatinized starch, dextrin, sucrose, lactose, calcium sulfate, calcium phosphate, and the binder may be selected from the group consisting of microcrystalline cellulose, mannitol, starch, lactose, calcium sulfate, calcium phosphate, and the like.
  • the surfactant may be selected from the group consisting of a Tween-based surfactant and sodium dodecylsulfonate.
  • the preparation method of the two-unit tablet of the invention is:
  • the material of the layer B as described above includes an active ingredient, an alkalizing agent, a disintegrating agent and other necessary excipients, pulverized, sieved, and mixed; or another preparation scheme, the active ingredient, alkalized The agent, and a part of other excipients such as a filler, a binder, mixed with an excipient having a retarding effect, granulated, dried, sized, and mixed with the remaining excipients to obtain a sheet B material.
  • the above-mentioned sheet A material and sheet B material are pressed into a two-layer sheet by a conventional two-layer sheet pressing method, or the sheet B material containing the active ingredient may be first tableted to obtain a core sheet B, and then a sheet is obtained.
  • the layer A material completely encloses the core B, and the tablet is packaged.
  • the method of dispersing the active ingredient in the carrier material having the retardation effect in the sheet B may also be carried out by: pulverizing the acid labile active ingredient and the carrier material separately, and sieving, Mix, with or without other ingredients, granulate, dry; or use fluidized bed granulation.
  • Layer A sodium hydrogencarbonate 350 to 800 mg, magnesium hydroxide 250 to 350 mg, heavy magnesium oxide 20 ⁇ 50 mg, filler 150 ⁇ 200 mg, disintegrant 50 ⁇ 100 mg, PVP K29/30 5 ⁇ 20 mg, add appropriate amount of magnesium stearate, mix evenly, get sheet A material.
  • some materials such as magnesium hydroxide and heavy magnesium oxide may be granulated.
  • Sheet B Dissolve 10 to 20 mg of PVP k29/32 and about 5 mg of sodium bicarbonate in an appropriate amount of water, with a unit effective dose of PPIs, sodium bicarbonate 95 to 345 mg, heavy magnesium oxide 20 to 70 mg, filler 30 to 40 mg, in a fluidized bed.
  • the obtained granules are mixed with 20 to 40 mg of a disintegrant, and 60 to 140 mg of a water-swellable polymer material and an appropriate amount of a lubricant to obtain a sheet B material.
  • Preparation Mix the two parts of the layer A and the sheet B separately, apply the two-layer tablet press, and press B first. In part, the A part is further compressed to obtain a PPIs bilayer tablet.
  • the preferred preparation form is: a sheet thickness of about 9.0 mm and a tablet weight of 1000 mg to 2000 mg.
  • the prepared PPIs tablets were tested for dissolution and acid resistance as follows:
  • Dissolution test using dissolution test (2005 version of the Pharmacopoeia Appendix XC third method) device, with acid solution (take sodium chloride 2.0 g, add hydrochloric acid 7.0 ml, add water to dissolve and dilute to 1000 ml, pH value 1.2) 150 ml
  • acid solution take sodium chloride 2.0 g, add hydrochloric acid 7.0 ml, add water to dissolve and dilute to 1000 ml, pH value 1.2
  • the rotation speed is 100 rpm, and operate according to law. Start the time of putting the double-layer tablet.
  • the rinse is transferred to a 250 ml brown vial and sonicated for 10 min.
  • Add water The solution of ethanol alkali solution (5: 3) is adjusted to the mark, shake well, centrifuge, filter, and accurately take 4 ml of the filtrate into a 10 ml brown volumetric flask, dilute to the mark with pHIO aqueous solution, shake well.
  • the component content was determined by high performance liquid chromatography to evaluate the acid resistance of the formulation.
  • the dissolution and acid resistance of the two-unit tablet of the present invention were measured, and as a result, the dissolution was 90% to 104%; under the conditions of the acid resistance test, the degradation of the active ingredient was remarkably lower than that of the comparative example. It is indicated that the release of the acid labile active ingredient of the present invention can be well controlled to better ensure the stability of the acid labile active ingredient.
  • PPIs also known as “proton pump inhibitors” refers to a benzimidazole compound that inhibits gastric acid secretion by a K+-ATPase system (proton pump) that irreversibly and specifically inhibits the secretory surface of cells in the parietal wall.
  • the PPIs of the present invention include all substituted benzimidazole PPIs, their salts, esters, amides, enantiomers, racemates, prodrugs, derivatives, etc., and are not limited to those compounds exemplified for illustration. .
  • alkaline and “basifying agent” as used herein have the same meaning and refer to a basic substance capable of neutralizing reaction with hydrochloric acid.
  • unit preparation refers to a preparation comprising an effective dose administered once, usually in the form of a separate preparation, such as a single tablet, which may contain the active ingredient as 10 mg, 20 mg, 40 mg of omeprazole, or 20 mg, 40 mg of pantoprazole, or 15 mg, 30 mg of lansoprazole, or 20 mg of rabeprazole.
  • an effective amount means an amount of active ingredient which, in accordance with the considerations known in the art, is effective to achieve pharmacological effects or therapeutic amelioration without excessive adverse side effects, such as PPIs from 2 mg/day to 300 mg/day. .
  • the prescription is as follows:
  • Preparation PVP k29/32 and 3 g sodium bicarbonate in layer B were dissolved in 200 ml of water, with pantoprazole sodium 44.7 g, sodium hydrogencarbonate 117 g, heavy magnesium oxide 20 g and mannitol 35 g Fluidized bed made of granules. The obtained granules were mixed with 20 g of PVPP XL 120 g pharmcoat 603 and an appropriate amount of magnesium stearate to obtain a sheet B material. Slice A The ingredients are comminuted and mixed. Using a two-layer tablet press, the B part is first pressed, and then the A part is pressed to obtain 1000 pieces of pantoprazole sodium double-layer tablet having a sheet thickness of about 9.0 mm.
  • the obtained two-layer sheet was subjected to measurement of dissolution and acid resistance, and the measurement method was as described above.
  • the dissolution was measured to be 96.6%.
  • Comparative Example 1 The pharm COa t 603 in the above-mentioned sheet B was removed, and the two-layer sheet was pressed as described above. The tablet of Example 1 and the tablet of this comparative example were subjected to acid resistance. The test method was as described above. The results are as follows:
  • the prescription is as follows:
  • Preparation The components in the layer A and the sheet B were separately pulverized and mixed. Using a two-layer tablet press, the B part is first pressed, and then the A part is pressed to obtain 1000 omeprazole double-layer tablets having a sheet thickness of about 9.0 mm.
  • the prescription is as follows:
  • the granules are granulated, dried at 50 to 60 ° C, and whole.
  • the obtained granules were mixed with 35 g of sodium carboxymethyl starch, 60 g of sodium carboxymethylcellulose, and an appropriate amount of magnesium stearate to obtain a sheet B material.
  • the components in the layer A are pulverized and mixed, and the two-layer tablet press is applied. First, the part B is pressed to obtain the core B, and then the core B is coated with the sheet A material to obtain 1000 lansoprazole double-layer chips.
  • the tablet has a thickness of about 10.0 mm.
  • the prepared double-layered chip was subjected to measurement of dissolution and acid resistance, and the measurement method was as described above.
  • the measured dissolution was 94.4%.
  • Comparative Example 3 The sodium carboxymethylcellulose in the above-mentioned sheet B was removed, and the two-layer sheet was pressed as described above.
  • the tablet of Example 3 and the tablet of the comparative example were subjected to acid resistance measurement, and the test method was as described above. The results are as follows: Sample acid resistance test results (% drug degradation, unit: %)
  • the prescription is as follows:
  • the obtained two-layer sheet was subjected to measurement of dissolution and acid resistance, and the measurement method was as described above.
  • the dissolution was measured to be 96.7%.
  • Comparative Example 4 The methyl cellulose in the above sheet B was removed, and the two-layer sheet was pressed as described above.
  • the tablet of Example 4 and the tablet of the comparative example were subjected to acid resistance measurement, and the test method was as described above. The results are as follows:
  • the prescription is as follows:
  • Preparation The components in the layer A and the sheet B were separately pulverized and mixed. Using a two-layer tablet press, the B part is first pressed, and then the A part is pressed to obtain 1000 pieces of rabeprazole double-layer tablet having a sheet thickness of about 9.0 mm.
  • the obtained two-layer sheet was subjected to measurement of dissolution and acid resistance, and the measurement method was as described above.
  • the dissolution was measured to be 101.2%.
  • Comparative Example 5 The sodium carboxymethylcellulose in the above-mentioned sheet B was removed, and the two-layer sheet was pressed as described above.
  • the tablet of Example 5 and the tablet of the comparative example were subjected to acid resistance measurement, and the test method was as described above. The results are as follows:

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un comprimé double d'un ingrédient actif labile sous l'action d'un acide, qui consiste en deux couches, à savoir une couche A et une couche B. La couche A comprend un agent basifiant et un désintégrant, et elle peut se désintégrer rapidement et libérer rapidement l'agent basifiant dans le suc gastrique ; la couche B comprenant un ingrédient actif labile sous l'action d'un acide, un agent basifiant, un désintégrant et un excipient ayant un effet retardateur.
PCT/CN2008/000475 2007-03-09 2008-03-10 Comprimé double comprenant un médicament labile sous l'action d'un acide WO2008110070A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2008800032753A CN101626755B (zh) 2007-03-09 2008-03-10 包含酸不稳定药物的双单元片剂

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNA2007100379658A CN101259108A (zh) 2007-03-09 2007-03-09 包含酸不稳定药物的双单元片剂
CN200710037965.8 2007-03-09

Publications (1)

Publication Number Publication Date
WO2008110070A1 true WO2008110070A1 (fr) 2008-09-18

Family

ID=39759000

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2008/000475 WO2008110070A1 (fr) 2007-03-09 2008-03-10 Comprimé double comprenant un médicament labile sous l'action d'un acide

Country Status (2)

Country Link
CN (2) CN101259108A (fr)
WO (1) WO2008110070A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112839635A (zh) * 2018-08-23 2021-05-25 株式会社钟根堂 包含埃索美拉唑及碳酸氢钠的具有优秀的释放特性的药剂学制剂
US11759428B2 (en) 2018-01-29 2023-09-19 Chong Kun Dang Pharmaceutical Corp. Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate
US11813285B2 (en) 2018-01-29 2023-11-14 Chong Kun Dang Pharmaceutical Corp. Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101843600A (zh) * 2009-03-23 2010-09-29 杭州锐思医药科技有限公司 质子泵抑制剂速释胶囊
EP4070789A4 (fr) * 2020-01-23 2024-01-24 Hanmi Pharm. Co., Ltd. Formulation composite pharmaceutique comprenant un inhibiteur de la pompe à protons et un antiacide
KR102573842B1 (ko) * 2020-02-21 2023-09-01 주식회사 종근당 방출특성이 우수한 에스오메프라졸 및 탄산수소나트륨의 약제학적 조성물
CN112022827B (zh) * 2020-09-30 2023-03-31 上海信谊天平药业有限公司 一种盐酸赛庚啶快速释放药物制剂及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
WO2006037766A1 (fr) * 2004-10-05 2006-04-13 Altana Pharma Ag Preparation pharmaceutique orale contenant un antagoniste de la pompe a protons et un excipient basique
WO2006116583A2 (fr) * 2005-04-26 2006-11-02 The Curators Of The University Of Missouri Compositions comprenant un benzimidazole polymerise et un tampon et procedes permettant de les utiliser

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
WO2006037766A1 (fr) * 2004-10-05 2006-04-13 Altana Pharma Ag Preparation pharmaceutique orale contenant un antagoniste de la pompe a protons et un excipient basique
WO2006116583A2 (fr) * 2005-04-26 2006-11-02 The Curators Of The University Of Missouri Compositions comprenant un benzimidazole polymerise et un tampon et procedes permettant de les utiliser

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11759428B2 (en) 2018-01-29 2023-09-19 Chong Kun Dang Pharmaceutical Corp. Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate
US11813285B2 (en) 2018-01-29 2023-11-14 Chong Kun Dang Pharmaceutical Corp. Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate
CN112839635A (zh) * 2018-08-23 2021-05-25 株式会社钟根堂 包含埃索美拉唑及碳酸氢钠的具有优秀的释放特性的药剂学制剂

Also Published As

Publication number Publication date
CN101259108A (zh) 2008-09-10
CN101626755B (zh) 2011-11-30
CN101626755A (zh) 2010-01-13

Similar Documents

Publication Publication Date Title
JP4865945B2 (ja) 経口の延長放出性医薬品剤形
JP5845173B2 (ja) 非オピオイドおよびオピオイド鎮痛薬の組み合わせを含む口腔内崩壊錠組成物
JP4638964B2 (ja) プロトンポンプ阻害剤およびｎｓａｉｄからなる経口用医薬剤形
US20070122470A1 (en) New Combination Dosage Form
JP2001524131A (ja) 安定な経口医薬品剤形
KR20000068914A (ko) 데스카르보에톡시로라타딘의 무 락토오스, 비흡습성 및 무수의 약제학적 조성물
WO2008110070A1 (fr) Comprimé double comprenant un médicament labile sous l'action d'un acide
SK284545B6 (sk) Orálna farmaceutická dávková forma s pulzačným uvoľňovaním
BRPI0714514B1 (pt) Grânulo compreendendo núcleo revestido por oxicodona, bem como comprimido para desintegração oral e seu processo de fabricação
WO2004112756A1 (fr) Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
AU2006213439A1 (en) Pharmaceutical composition of acid labile substances
US20040166162A1 (en) Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
JP7482182B2 (ja) プロトンポンプ阻害剤を含む経口用固形製剤組成物、それを含む経口用固形製剤及びその製造方法
US8758818B2 (en) Oral tablet compositions of dexlansoprazole
JP5749247B2 (ja) 経口用徐放性固形製剤
TW202227066A (zh) 為錠劑形式之含奧美拉唑、埃索美拉唑或其醫藥上可接受鹽之醫藥組成物及其製備程序
PT2316454E (pt) Forma de dosagem contendo pantoprazole como ingrediente activo
US20140255484A1 (en) Modified release pharmaceutical compositions of dexlansoprazole
TW200413032A (en) Oral extended release tablets and methods of making and using the same
WO2009137648A1 (fr) Pastilles multicouches inhibant la pompe à protons
WO2022116796A1 (fr) Pellet gastro-résistant, son procédé de préparation et préparation le comprenant
KR100754239B1 (ko) 염산세티리진과 염산슈도에페드린을 함유하는 제어방출성의 경구용 제제 및 그의 제조방법
KR20040005257A (ko) 방출제어형 약제학적 조성물
BRPI0619391A2 (pt) forma de dosagem farmacêutica oral, processo para a manufatura de uma forma de dosagem de combinação fixa oral, uso de uma forma de dosagem, e, forma de combinação fixa oral farmacêutica

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880003275.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08714928

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08714928

Country of ref document: EP

Kind code of ref document: A1